MRKR - צמיחת מכירות משנה לשנה (TTM) markertherapeutics.com

Marker Therapeutics is optimizing its biomaterial supply chains, which minimizes raw material shortages and supports profitability. The trailing twelve months (TTM) revenue change illustrates income dynamics, where -76.90 determines the current status of the parameter. Financial potential relies on the commercialization of T-cell therapies, although the high burn rate and the success of leukemia trials remain key risk factors.
פילוחי נתונים אנליטיים מרוכזים עבור Marker Therapeutics (MRKR)

Monitoring the dynamics of incoming cash flows is critical for assessing the issuer's financial stability. This indicator calculates the percentage deviation of total revenue over the last 12 months relative to the same window from the previous year. For Marker Therapeutics (MRKR), which scales cancer immunotherapy through grants, this calculation reflects the efficiency of attracting external funding. By analyzing the relative change in rolling year revenue versus the prior year period, an investor can determine the company's pace of commercial development.